RecruitingPhase 2NCT07118618
Probenecid Administration for Alcohol Craving and Consumption
Probenecid, Pannexin 1 Channels for Alcohol Use Disorder
Sponsor
Brown University
Enrollment
120 participants
Start Date
Mar 14, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- • Male or female, ≥18 years.
- women \>7 drinks/week; men \>14 drinks/week.
- meet moderate to severe AUD score for DSM-5 criteria.
- Breath Alcohol Content (BrAC)=0.00 at each visit.
- in good health as confirmed by medical history, physical examination and lab tests.
- willing to adhere to the study procedures.
- understand informed consent and questionnaires in English at an 8th grade level.
Exclusion Criteria10
- • Women who are breastfeeding or positive urine test for pregnancy.
- clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \>150% of the upper normal limit, ALT/AST \>300% the UNL, creatinine clearance ≤60 dl/min
- meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses
- medications that reduce alcohol consumption (naltrexone, disulfiram).
- use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration).
- history of suicide attempts in the last three years.
- current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.
- current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.
- current use of medications that may interact with probenecid.
- history of hypersensitivity to sulfa drugs.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGProbenecid Oral Tablet
2gr daily
DRUGPlacebo Oral Tablet
Inactive compound
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07118618
Related Trials
MPFC Theta Burst Stimulation as a Treatment Tool for Alcohol Use Disorder: Effects on Drinking and Incentive Salience
NCT049989161 location
Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community
NCT068037063 locations
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
NCT070405921 location
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
NCT041358461 location
Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder
NCT065828881 location